The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Blood and Marrow Transplant Unit, Westmead Hospital, Sydney, Australia; Sydney Cell and Gene Therapy Laboratory, Westmead Hospital, Sydney, Australia.
Biol Blood Marrow Transplant. 2018 Jan;24(1):71-77. doi: 10.1016/j.bbmt.2017.08.028. Epub 2017 Aug 31.
Adoptive cellular immunotherapy has been shown to be effective in the management of cytomegalovirus (CMV) reactivation and disease. Whether adjuvant dendritic cell (DC) vaccination will provide additional benefit in prophylaxis or treatment of CMV in hematoietic cell transplantation (HSCT) recipients is unknown. In this study, we administered prophylactic CMV-peptide specific T cell infusions, followed by 2 doses of intradermal CMV peptide-pulsed DC vaccine, to 4 HSCT recipients. There were no immediate adverse events associated with T cell infusion or DC vaccinations. One of the 4 patients developed grade III acute gut graft-versus-host disease. Immune reconstitution against CMV was detected in all 4 patients. Patients receiving CMV peptide-specific T cells and DC vaccination had peak immune reconstitution at least 10 days after the second DC vaccination. In summary, combining DC vaccine with T cell infusion appears feasible, although further study is required to ascertain its safety and efficacy in augmenting the effects of infusing donor-derived CMV-specific T cells.
过继性细胞免疫疗法已被证明在巨细胞病毒 (CMV) 再激活和疾病的治疗中有效。在造血细胞移植 (HSCT) 受者中，辅助树突状细胞 (DC) 疫苗接种在 CMV 的预防或治疗中是否会提供额外的益处尚不清楚。在这项研究中，我们给 4 名 HSCT 受者预防性输注 CMV 肽特异性 T 细胞，然后进行 2 剂皮内 CMV 肽脉冲 DC 疫苗接种。T 细胞输注或 DC 疫苗接种没有立即发生不良事件。4 名患者中的 1 名出现 3 级急性肠道移植物抗宿主病。4 名患者均对 CMV 产生免疫重建。接受 CMV 肽特异性 T 细胞和 DC 疫苗接种的患者在第二次 DC 疫苗接种后至少 10 天达到免疫重建高峰。总之，将 DC 疫苗与 T 细胞输注相结合似乎是可行的，尽管需要进一步研究来确定其在增强输注供体来源的 CMV 特异性 T 细胞的效果方面的安全性和有效性。
